WGS stock forecast, quote, news & analysis
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders... Show more
Why GeneDx Holdings (WGS) Stock Is Down -34% in the Last 30 Days
Key Takeaways
- GeneDx Holdings (WGS) fell roughly 34% over the 30 days ending October 23, 2026, sliding from $85.20 to $56.15, including a 16.4% single-session decline.
- The selloff erased a mid-September rally that had carried shares above $104, leaving the stock near the lower end of its recent trading range.
- Primary drivers include the Centers for Medicare & Medicaid Services' (CMS) proposed 2027 reimbursement cuts for exome and genome sequencing, a short-seller report on alleged billing practices, and insider selling.
- Operating fundamentals remain solid on volume: second-quarter 2026 revenue reached $114.4 million (up 11% year over year), with exome and genome volume up 32% and adjusted gross margin near 70%.
- Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million; third-quarter results are scheduled for November 9, 2026.
- Wall Street's consensus remains a "Moderate Buy," with average price targets clustered near $90, well above the recent share price.
- For additional detail on Price Targets, Earnings, and Forecast, explore GeneDx's dedicated analysis pages.
- Discover how algorithmic strategies are approaching this and other names by exploring Trending AI Robots.
GeneDx Holdings (WGS) Company Overview and Market Position
GeneDx Holdings Corp. is a genomics diagnostics company specializing in whole exome and whole genome sequencing for pediatric and rare-disease diagnosis. The company translates complex genomic data into actionable clinical answers, helping clinicians diagnose conditions that standard testing often misses. Beyond diagnostics, GeneDx provides data and interpretation services to biopharma and health-system partners and has expanded its AI-based analysis platform through the acquisition of Fabric Genomics.
Investors follow WGS closely because it sits at the center of several long-term healthcare themes: the shift toward precision medicine, growing adoption of genomic newborn screening, and expanding payer coverage for exome and genome testing. The company's proprietary rare-disease dataset, established clinical reputation, and the GUARDIAN newborn screening study are central to its competitive positioning.
GeneDx Holdings (WGS) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 days ending October 23, 2026, WGS declined approximately 34%, from a closing price of $85.20 on September 23 to $56.15. The move was punctuated by a 16.4% single-day drop on October 23, the steepest session of the period and a sharp reversal from the stock's intra-period peak of $104.95 reached on September 17.
The broader quarterly picture is similar in character but smaller in net magnitude. From roughly $65 in late July, WGS advanced toward its September high before surrendering all of those gains and more, ending the three-month window down roughly 14%. The chart pattern reflects a rally driven by improving second-quarter results and momentum in newborn screening, followed by a decisive retreat as reimbursement and cash-burn concerns reasserted themselves.
What Drove WGS Stock Price in the Last 30 Days
The recent decline has been driven by a combination of regulatory, governance, and sentiment factors rather than a single fundamental breakdown. On September 22, CMS proposed reductions to 2027 exome and genome sequencing reimbursement rates as part of its clinical laboratory fee schedule, sending shares down more than 9% in a session. Although analysts at Craig-Hallum estimated the direct revenue impact at only about 1% annually, the proposal amplified investor anxiety around GeneDx's average reimbursement rate, a metric that has been a focal point since the company cut its 2026 guidance earlier in the year.
That pressure was compounded by a short-seller report alleging billing and reimbursement concerns, and by insider activity. Chief Executive Officer Katherine Stueland sold approximately $1.03 million of stock in mid-September, and additional executive sales followed, reinforcing negative sentiment even as filings indicated many sales related to tax obligations on equity awards.
Persistent losses and cash burn added to the unease. GeneDx reported a second-quarter operating cash burn of about $39 million, and while management has characterized the second quarter as the peak of that burn, the pace of spending remains a central investor concern. Together, these factors overwhelmed the company's otherwise constructive operating news during the period.
What Drove WGS Stock Performance Over the Last Quarter
The quarterly narrative is one of a strong operational story colliding with reimbursement uncertainty. GeneDx's second-quarter results, reported August 3, beat expectations: revenue of $114.4 million exceeded the $111 million consensus, exome and genome volume grew 32% year over year, adjusted gross margin improved to 70%, and the company returned to adjusted profitability a quarter earlier than expected. Management also highlighted a major commercial genome coverage expansion, from 47% to 87% of covered lives.
Those results helped fuel the stock's climb toward $105 by mid-September. However, the same themes that triggered the earlier selloff — deteriorating blended reimbursement rates, the first-quarter revenue guidance cut from $540-$555 million to $475-$490 million, a $31.3 million impairment tied to Fabric Genomics, and related securities class-action litigation — never fully left the narrative. When the CMS proposal and short-seller scrutiny resurfaced those worries, the quarterly gains reversed quickly.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader platform offering hundreds of AI-driven bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies currently generating momentum. The robots vary widely in approach, holding period, and performance metrics, allowing users to compare systems that align with different risk profiles and time horizons. For investors and traders seeking a data-driven, systematic perspective on names like WGS, the Trending AI Robots page provides a practical starting point for exploring automated market analysis.
WGS Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape WGS in the months ahead. The most immediate is the company's third-quarter 2026 earnings report, scheduled for November 9, when investors will assess revenue against the $122-$124 million guidance, exome and genome volume, and whether blended average reimbursement rates begin to recover. Progress on collections — management has targeted moving toward an industry-standard collection rate — will be closely scrutinized.
On the regulatory front, the finalization of the CMS 2027 reimbursement schedule, along with any updates on commercial coverage policies, could materially affect sentiment. Continued enrollment and data from the GUARDIAN newborn screening study and the NIH-funded BRIDGES-NBS program represent longer-term volume catalysts. Investors will also monitor cash-burn trajectory, the resolution of outstanding class-action litigation, and any further insider or institutional positioning changes. These developments, rather than short-term price action, will likely determine whether the stock can stabilize and rebuild investor confidence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
WGS in +13.20% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where WGS advanced for three days, in 232 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where WGS's RSI Oscillator exited the oversold zone, 30 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on WGS as a result. In 65 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for WGS just turned positive on October 28, 2026. Looking at past instances where WGS's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
The 50-day moving average for WGS moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
WGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
WGS moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for WGS crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for WGS entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.433) is normal, around the industry mean (67.473). P/E Ratio (-19.025) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties